Metformina + Pioglitazona Biofarmoz

Metformin hydrochloride and pioglitazone, the active ingredient in Metformina + Pioglitazona Biofarmoz, is a biguanide; thiazolidinedione presented as an oral tablet for systemic use. It is indicated for the management of type 2 diabetes mellitus in adults when diet, exercise and monotherapy are insufficient. GNH USA supplies Metformina + Pioglitazona Biofarmoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metformina + Pioglitazona combines two oral antidiabetic agents to improve glycemic control in type 2 diabetes mellitus. - Type 2 diabetes mellitus (fasting glucose): lowers fasting plasma glucose levels. - Type 2 diabetes mellitus (post‑prandial glucose): reduces post‑prandial glucose excursions. - Type 2 diabetes mellitus (combination therapy): enhances overall glycemic control when added to other oral agents or insulin.

The following adverse reactions have been reported with the combination of metformin and pioglitazone.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: loose stools, often transient. - Abdominal discomfort: cramping or pain. - Headache: mild tension‑type headache. - Edema: peripheral swelling, especially in the lower limbs. - Weight gain: modest increase in body weight.

Serious or Rare Side Effects: - Lactic acidosis: rare but life‑threatening metabolic disturbance. - Hepatic failure: severe liver injury, particularly in patients with pre‑existing liver disease. - Congestive heart failure: fluid retention leading to decompensation. - Bone fracture: increased risk of femoral fractures with long‑term use.

When prescribing Metformina + Pioglitazona, clinicians should consider several safety aspects. - Renal impairment: assess kidney function before initiation and monitor periodically. - Hepatic impairment: avoid in patients with significant liver disease. - Lactic acidosis risk: discontinue if signs of hypoxia, severe infection, or acute heart failure occur. - Heart failure: use with caution; monitor for signs of fluid overload. - Pregnancy and breastfeeding: safety not established; avoid unless benefits outweigh risks. - Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Metformina + Pioglitazona may interact with several medicines, requiring clinical attention.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate acute renal failure, increasing metformin accumulation. - Strong CYP2C8 inhibitors (e.g., gemfibrozil): raise pioglitazone plasma levels, heightening toxicity. - Insulin or sulfonylureas: combined use can cause severe hypoglycemia.

Moderate Interactions (Monitor Closely): - Diuretics: risk of dehydration and renal dysfunction. - Corticosteroids: may blunt glucose‑lowering effect, requiring dose adjustment. - Beta‑blockers: can mask hypoglycemia symptoms. - NSAIDs: may impair renal clearance of metformin.